Literature DB >> 32159390

Rationale for IL-15 superagonists in cancer immunotherapy.

Karin M Knudson1, James W Hodge1, Jeffrey Schlom1, Sofia R Gameiro1.   

Abstract

Entities:  

Keywords:  CD8 T cells; IL-15 superagonist; NK cells; immune activation

Year:  2020        PMID： 32159390     DOI： 10.1080/14712598.2020.1738379

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN： 1471-2598            Impact factor:   4.388


× No keyword cloud information.
  17 in total

1.  NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells.

Authors:  Tanya O Robinson; Shweta M Hegde; Allison Chang; Achintyan Gangadharan; Sarai Rivas; Loui Madakamutil; Jonathan Zalevsky; Takahiro Miyazaki; Kimberly S Schluns
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 14.808

Review 2.  Harnessing cytokines and chemokines for cancer therapy.

Authors:  David J Propper; Frances R Balkwill
Journal:  Nat Rev Clin Oncol       Date:  2022-01-07       Impact factor: 65.011

3.  Insights into the anticancer mechanisms of interleukin-15 from engineered cytokine therapies.

Authors:  Zachary J Bernstein; Jamie B Spangler
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 19.456

Review 4.  Therapeutic potential of interleukin-15 in cancer (Review).

Authors:  Gheorghita Isvoranu; Mihaela Surcel; Adriana Narcisa Munteanu; Ovidiu Gabriel Bratu; Florentina Ionita-Radu; Monica Teodora Neagu; Marioara Chiritoiu-Butnaru
Journal:  Exp Ther Med       Date:  2021-04-24       Impact factor: 2.447

Review 5.  Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink.

Authors:  John A Hangasky; Thomas A Waldmann; Daniel V Santi
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

6.  Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.

Authors:  Kellsye P Fabian; Michelle R Padget; Rika Fujii; Jeffrey Schlom; James W Hodge
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

Review 7.  Targeting ubiquitin signaling for cancer immunotherapy.

Authors:  Xiaofei Zhou; Shao-Cong Sun
Journal:  Signal Transduct Target Ther       Date:  2021-01-13

8.  NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.

Authors:  Takahiro Miyazaki; Mekhala Maiti; Marlene Hennessy; Thomas Chang; Peiwen Kuo; Murali Addepalli; Palakshi Obalapur; Sara Sheibani; Joanna Wilczek; Rhoneil Pena; Phi Quach; Janet Cetz; Andrew Moffett; Yinyan Tang; Peter Kirk; Jicai Huang; Dawei Sheng; Ping Zhang; Werner Rubas; Loui Madakamutil; Saul Kivimäe; Jonathan Zalevsky
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 12.469

9.  Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy.

Authors:  Mary-Keara Boss; Remy Watts; Lauren G Harrison; Sophie Hopkins; Lyndah Chow; Erin Trageser; Carina Easton; Susan M LaRue; Daniel Regan; Mark W Dewhirst; Steven Dow
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

10.  Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing.

Authors:  Benjamin Wolfson; Michelle R Padget; Jeffrey Schlom; James W Hodge
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.